Raymond James reiterates QXO stock rating on earnings beat

Raymond James reiterated an Outperform rating and $21.00 price target for QXO Inc (NASDAQ:QXO), citing strong Q3 EBITDA and encouraging Q4 trends. The stock trades at $12.60, with management projecting double-digit organic sales growth and 20-25% incremental margins through 2030. Other analysts have adjusted price targets, with DA Davidson and Truist Securities maintaining Buy ratings but lowering targets to $19 and $15, respectively, due to operating costs and market conditions.

Original reporting
Published Nov 16, 2026, 2:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$QXO
Bullish
medium confidence
Mentioned
$QXO
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$QXOBullishLow
01

Why it matters

For traders, the main incremental signal is the reiterated Outperform stance with a $21 target, plus the mention that options positioning implies a potential earnings-driven move, though timing is not confirmed.

02

Market read

Single-name analyst reiteration with a valuation narrative; useful for sentiment and positioning but not a new fundamental disclosure.

03

What to watch

The piece relies on valuation assumptions (EV/EBITDA multiple, growth and margin scenarios) rather than new guidance; traders may focus on whether Q4 trends persist and on the timing/confirmation of the upcoming earnings report.

Relevance 4/10Novelty 3/10Timing: analyst note context, no new scheduled catalyst stated

Background

The article frames QXO’s recent pre-announced Q3 results and ongoing Q4 trends, then summarizes Raymond James’ valuation approach and reiterated rating.

Company-level read

Ticker impact

$QXOBullishMedium confidence
Context

Raymond James reiterated an Outperform rating and $21 price target after QXO’s Q3 EBITDA beat and encouraging Q4 trends to date.

Expected impact

Likely modest upward bias as the market weighs the reiterated Outperform call and the $21 target against the current ~$12.60 price.

Evidence & confidence

The article is an analyst reiteration tied to specific operating takeaways (Q3 EBITDA beat, Q4 trends) and a detailed valuation narrative, but it is not a fresh company disclosure.

Market effects

Limited sector read-through; this is primarily single-name valuation and earnings-trend framing.

None indicated.

None indicated.

Counterpoint

Other banks cited in the article cut price targets (Truist to $15 from $26) due to rising operating costs and weak market conditions, suggesting upside may be capped if margins deteriorate.

Key entities

  • QXO Inc

    NASDAQ-listed company discussed as having a Q3 EBITDA beat and encouraging Q4 trends, with analyst valuation debate around growth and margins.

  • Raymond James

    Reiterated Outperform rating and $21 price target for QXO, citing Q3 EBITDA beat and valuation framework.

  • DA Davidson

    Adjusted price target to $19 from $20 while maintaining Buy rating, per the article.

  • Truist Securities

    Reduced price target to $15 from $26 while maintaining Buy rating, per the article.

Related articles

$QXOMed

DA Davidson lowers QXO stock price target to $19 on results

DA Davidson lowered its price target for QXO Inc. (NASDAQ:QXO) to $19 from $20, maintaining a Buy rating. The firm noted QXO's third-quarter 2026 results met lowered expectations, with TopBuild outperforming and Beacon, Kodiak aligning with projections. QXO's stock trades at $12.81, offering potential 48% upside to the new target. Analysts predict profitability this year, citing undervaluation and recent momentum. Earnings are due November 6, with options data suggesting a 3.1% move.

$QXOMed

QXO Sets 2027 CFO Transition, Moving Essaid to Vice Chairman

QXO has appointed Dev Ahuja, current finance chief at Novelis, as its future CFO, effective January 2027. Current CFO Ihsan Essaid will transition to vice chairman, focusing on acquisitions and fundraising. QXO aims for $50 billion in annual revenue by 2033, driven by M&A and organic growth. Ahuja brings over 20 years of financial experience, including roles at Alcon and Novartis.

$QXOMedAI 8/10

QXO Reports Third Quarter 2026 Results

QXO, Inc. (QXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 QXO Reports Third Quarter 2026 Results GREENWICH, Conn. — November 12, 2026 — QXO, Inc. (“QXO” or the “Company”) (NYSE: QXO) today reported financial results for the third quarter of 2026. For the three months ended September 30, 2026, basic and diluted loss per comm